COLOPLAST A/S/ADR (CLPBY) Downgraded to “Sell” at Zacks Investment Research
Zacks Investment Research lowered shares of COLOPLAST A/S/ADR (OTCMKTS:CLPBY) from a hold rating to a sell rating in a report issued on Tuesday.
According to Zacks, “Coloplast A/S develops and provides health care products and services. Its operating business segments consist of Chronic Care, Urology Care and Wound & Skin Care. The Chronic Care segment covers the sale of ostomy care products and continence care products. The Urology Care segment offers urological products, including disposable products. The Wound and Skin Care segment covers the sale of wound and skin care products. Coloplast A/S is headquartered in Humlebaek, Denmark. “
Separately, ValuEngine raised shares of COLOPLAST A/S/ADR from a hold rating to a buy rating in a research note on Thursday, February 28th.
COLOPLAST A/S/ADR (OTCMKTS:CLPBY) last released its quarterly earnings results on Tuesday, February 5th. The company reported $0.07 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.07. COLOPLAST A/S/ADR had a net margin of 23.17% and a return on equity of 70.14%. The company had revenue of $660.80 million for the quarter. As a group, equities research analysts expect that COLOPLAST A/S/ADR will post 0.3 EPS for the current fiscal year.
About COLOPLAST A/S/ADR
Coloplast A/S develops and markets intimate healthcare products and services worldwide. The company operates through three segments: Chronic Care, Interventional Urology, and Wound & Skin Care. It provides ostomy care products, including SenSura Mio, which provides fit to individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand.
Featured Story: Trading Stocks – What are percentage gainers?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for COLOPLAST A/S/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for COLOPLAST A/S/ADR and related companies with MarketBeat.com's FREE daily email newsletter.